Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: Characterizing a phenotype

99Citations
Citations of this article
117Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Aims: Risk stratification for sudden death in arrhythmogenic right ventricular cardiomyopathy (ARVC) is challenging in clinical practice.We lack recommendations for the risk stratification of exclusive left-sided phenotypes. The aim of this studywas to investigate genotype-phenotype correlations in patients carrying a novelDSP c.1339C>T, and to review the literature on the clinical expression and the outcomes in patients with DSP truncating mutations. Methods and results: Genetic screening of the DSP gene was performed in 47 consecutive patients with a phenotype of either an ARVC (n = 24) or an idiopathic dilated cardiomyopathy (DCM), who presented with ventricular arrhythmias or a family history of sudden death (n = 23) (aged 40±19 years, 62% males). Three unrelated probands with DCM were found to be carriers of a novel mutation (c.1339C>T). Cascade family screening led to the identification of 15 relatives who are carriers. Penetrance in c.1339C>T carrierswas 83%. Sustained ventricular tachycardia was the first clinical manifestation in six patients and nine patientswere diagnosed with left ventricular impairment (two had overt severe disease and seven had a mild dysfunction). Cardiac magnetic resonance revealed left ventricular involvement in nine cases and biventricular disease in three patients. Extensive fibrotic patterns in six and non-compaction phenotype in five patients were the hallmark in imaging. Conclusion: DSP c.1339C>T is associated with an aggressive clinical phenotype of left-dominant arrhythmogenic cardiomyopathy and left ventricular non-compaction. Truncating mutations in desmoplakin are consistently associated with aggressive phenotypes and must be considered as a risk factor of sudden death. Since ventricular tachycardia occurs even in the absence of severe systolic dysfunction, an implantable cardioverter-defibrillator should be indicated promptly. Published on behalf of the European Society of Cardiology. All rights reserved.

Cite

CITATION STYLE

APA

López-Ayala, J. M., Gómez-Milanés, I., Muñoz, J. J., Ruiz-Espejo, F., Ortíz, M., González-Carrillo, J., … Gimeno, J. R. (2014). Desmoplakin truncations and arrhythmogenic left ventricular cardiomyopathy: Characterizing a phenotype. Europace, 16(12), 1838–1846. https://doi.org/10.1093/europace/euu128

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free